康方生物否认向患者销售“临床研究用药”：销售人员伪造材料从公司骗取若干药物

Core Viewpoint - The recent controversy surrounding the clinical trial cancer drug, Cadonilimab, developed by Kangfang Biopharma, has drawn significant industry attention due to allegations of improper patient charging and drug distribution practices [1] Group 1: Company Actions - Kangfang Biopharma issued a statement clarifying that they never charged patient Li Moumei for the clinical research drug and that their sales personnel did not collect any fees from her [1] - The company emphasized that the drug provided to Li Moumei was obtained through fraudulent means by sales personnel who forged research initiation documents and hospital ethics approvals [1] - The company highlighted that the drug given to the patient was produced in strict accordance with national GMP standards, ensuring the same quality management as commercially sold products [1] Group 2: Patient Situation - The sales personnel provided the drug to Li Moumei for free, considering her limited financial capacity and the positive therapeutic effects she experienced from using Cadonilimab [1]